Trials / Completed
CompletedNCT00805441
A Study in the Treatment of Alcohol Dependence.
A Phase 2 Study of LY686017 Compared With Placebo for the Treatment of Alcohol Dependence
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 190 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
H8R-MC-HJAQ is a Phase 2, parallel, double-blind, randomized study comparing LY686017 with placebo in a 12-week trial that includes Medical Management. This study is an outpatient study in which approximately 180 alcohol dependent subjects will be enrolled. Subjects will be randomized in a 1:1 fashion to LY686017 or placebo, and will receive once daily dosing for twelve weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY686017 | 50 milligrams (mg) daily by oral route for 12 weeks |
| DRUG | Placebo | Daily by oral route for 12 weeks |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2008-12-09
- Last updated
- 2019-09-17
- Results posted
- 2018-02-13
Locations
21 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00805441. Inclusion in this directory is not an endorsement.